

To,  
The Chief General Manager  
Listing Operation, BSE Limited,  
20<sup>th</sup> Floor, P.J. Towers,  
Dalal Street,  
Mumbai – 400 001.

Dear Sir,

**Sub: Application for “In-principle approval” prior to issue and allotment of (6,75,000 Equity Shares and 33,00,000 Warrants) on preferential basis under Regulation 28(1) of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015.**

- I, CA. Narendra Rajput, partner of SSNR & Co., Chartered Accountants, hereby certify that the minimum issue price for the proposed preferential issue of Eiko LifeSciences Limited, based on the pricing formula prescribed under Regulation 164 / 165 of Chapter V of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 has been worked out at Rs. 55.
- The relevant date for the purpose of said minimum issue price was 08<sup>th</sup> December 2025.
- The working for arriving at such minimum issue price are based on valuation report from Independent Registered Valuer. A Brief Synopsis are as follows:

ICDR Regulations	Amount
Based on valuation report, fair Value of equity share as per regulation 166A of ICDR Regulations – A	45.00
Fair Value of equity share as per Regulations 164 of ICDR Regulations – B	54.98 (round off to 55.00)
<b>Minimum price at which shares should be issued (Higher of A or B above)</b>	<b>55.00</b>

- The highest trading volume in respect of the equity shares of the issuer has been recorded during the preceding 90 trading days prior to the relevant date on Bombay Stock Exchange
- We hereby certify that the Articles of Association of the issuer does not provide for a method of determination which results in a floor price higher than that determined under ICDR Regulations, 2018.

**For SSNR & Co.**

Chartered Accountants

**FRN.: 152106W**



**CA. Narendra Rajput**

Partner

**Membership No. 036588**



**Place: Mumbai**

**Date: 11-12-2025**

**UDIN: 25036588BMICIA6567**